The Swisscom-backed genomic testing platform has now raised more than $60m, having closed a series D round led by Balderton Capital.

Sophia Genetics, a Switzerland-based clinical genomics technology provider that counts telecommunications firm Swisscom as an investor, completed a $30m series D round led by venture capital firm Balderton Capital yesterday.

The round included VC firm 360º Capital Partners, VC fund Invoke Capital and Alychlo, the investment vehicle for pharmaceutical entrepreneur Marc Coucke. It increased Sophia’s overall funding to approximately $62m.

Sophia has created a clinical genomics analytics platform called Sophia AI that helps physicians diagnose and treat patients more effectively.…